Preferred Label : Anti-B7-H3 Antibody-drug Conjugate ILB-3101;
NCIt synonyms : Anti-B7-H3 ADC ILB-3101;
NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1)
monoclonal antibody directed against the tumor-associated antigen (TAA) and T-cell
checkpoint ligand B7-homologue 3 (B7-H3, CD276) conjugated to the cytotoxic agent
eribulin, a synthetic, macrocyclic ketone analogue of halichondrin B, with potential
antineoplastic activity. Upon administration of anti-B7-H3 ADC ILB-3101, the anti-B7-H3
monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon
binding and internalization, eribulin targets and binds to the vinca domain of tubulin
and inhibits both the polymerization of tubulin and the assembly of microtubules.
This inhibits mitotic spindle assembly, induces cell cycle arrest at G2/M phase, and
results in apoptosis of B7-H3-expressing tumor cells. In addition, ILB-3101 induces
a potent bystander effect in neighboring tumor cells and immunogenic cell death (ICD).
B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein
superfamily, is an immunoregulatory protein overexpressed on certain tumor cell types
and on various immune cells. It is a negative regulator of the T-cell activation and
its overexpression plays a key role in tumor cell invasion and metastasis.;
Molecule name : ILB-3101; ILB 3101;
Origin ID : C217334;
concept_is_in_subset
- has_target
